AbbVie
ABBV Big PharmaImmunology and oncology specialist spun from Abbott in 2013. Humira successor portfolio includes Skyrizi and Rinvoq. Expanded into aesthetics via Allergan acquisition.
FDA Novel Drug Designations
(2016-2025)AbbVie at a Glance
- Leading 6 drug targets across portfolio
- Fast trial execution (25 months median completion)
AbbVie's Key Drugs
AbbVie's core commercial portfolio centers on SKYRIZI, RINVOQ, VRAYLAR, spanning Immunology and Oncology — its most strategically important drugs approved in the last 15 years.
Moderate-to-severe plaque psoriasis
Moderately to severely active rheumatoid arthritis
Schizophrenia
Chronic lymphocytic leukemia (CLL)
Migraine
AbbVie News
All AbbVie news →- Nov 8, 2026 TrialsAllergan Aesthetics Reports Improved Satisfaction With Facial Appearance Following Aesthetic Treatment in Two Studies of Patients on GLP-1 Medications ↗
- Nov 3, 2026 TrialsAllergan Aesthetics to Present New Research on Aesthetic Care Following Medical Weight Loss and Evolving Patient Needs at ASDS 2026 ↗
- Oct 30, 2026 EarningsAbbVie Reports Third-Quarter 2026 Financial Results ↗
- Oct 27, 2026 RegulatoryAbbVie Submits Biologics License Application (BLA) for Etentamig to U.S. FDA for Adults Living With Relapsed/Refractory Multiple Myeloma ↗
- Oct 23, 2026 RegulatoryU.S. FDA Approves Subcutaneous Induction Regimen for AbbVie's SKYRIZI® (risankizumab-rzaa) for Adults With Moderately to Severely Active Crohn's Disease ↗
AbbVie's Recent FDA Approvals
AbbVie secured 4 new FDA approvals for novel drugs (NDA/BLA) in the last two years.
AbbVie's Therapeutic Areas
AbbVie's approved drugs and pipeline span 5 therapeutic areas, led by Immunology and Oncology, across 8 biologic and 55 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
AbbVie's Top Competitors
AbbVie's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Roche, and Bristol-Myers Squibb. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
AbbVie Pipeline Snapshot
AbbVie has 676 active clinical programs from ClinicalTrials.gov — 250 Phase 3, 180 Phase 2 and 246 Phase 1.
Phase 3 Readout Calendar Pro
8 Phase 3 trials with confidence-graded primary completion dates.
Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.
Pro Intelligence Preview
Deep insights for investors and analysts
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 168/252 completed
- • Speed: 25 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
Active (27)
Discontinued (9)
Company Info
- First Approval
- 1944-07-31
- Latest
- 2026-10-23
- Applications
- 228
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges